Press Releases

Investor Resources
Contact Us
Investor ResourcesPress Releases

Press Releases

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science that Supports Development of its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure


February 20, 2025

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference


February 4, 2025

Cardiol Therapeutics’ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024


November 18, 2024

Cardiol Therapeutics to Advance CardiolRx™ into a Late-stage Trial in Patients with Recurrent Pericarditis


October 22, 2024

Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option


October 11, 2024

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares


October 10, 2024

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares


October 9, 2024

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares


October 8, 2024

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx™ for Acute Myocarditis


September 24, 2024

2025 Cardiol Therapeutics. All right reserved.